# Thederma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thederma

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.thederma.com
- Total disclosed funding: $29M
- Latest round: Series A (Oct 23, 2024)
- Investors on record: 4

## About

Established in 2021 and based in Shanghai, China, Thederma is a company developing innovative drugs for immune-mediated diseases, focusing on the development of therapeutics for autoimmune inflammatory diseases related to AhR targets. The company's CEO, Dr. Geng-Hui Chen, is the co-inventor of the topical drug for the AhR target and personally holds more than 30 pharmaceutical invention patents. The company was rated as a Shanghai Specialized, Refined, Featured and Original SME and a Shanghai Pudong New Area Postdoctoral Innovation and Practice Base. In October 2024, Thederma raised approximately CNY 100 million in series A+ funding.

Thederma focuses on the field of immune-mediated diseases, especially the development of drugs for the treatment of autoimmune inflammatory diseases related to the AhR target. The company's drugs can be used to treat diseases of the central nervous system, five sense organs, respiratory and skin diseases.

The company generates revenue by developing drugs for the treatment of autoimmune inflammatory diseases related to the AhR target.

The company will use the series A+ funding for the research and development, clinical research and commercial promotion of therapeutic drugs for autoimmune inflammatory diseases such as the aryl hydrocarbon receptor (AhR) target.

## Funding rounds

- Series A, Oct 23, 2024, $14M — Beida Fund, Hankang Capital, Qingdao Conson Development (Group), Shanghai BaiNuo Private Equity Fund Management
- Series A, Mar 10, 2023, $15M — Beida Fund, Hankang Capital, Shanghai BaiNuo Private Equity Fund Management
- Angel, Jun 30, 2021 — Hankang Capital

## Investors

- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Angel, Series A
- Beida Fund (https://capitalatlas.ai/funds/beida-fund) — Series A
- Shanghai BaiNuo Private Equity Fund Management — Series A
- Qingdao Conson Development (Group) — Series A